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Summary 
Specific  HLA molecules  have recently been shown  to confer target cell resistance  to lysis by 
some  CD3-  natural  killer  (NK)  cells.  For  certain  NK  clones,  resistance  is governed by two 
specificities (NK1 and NK2) that are associated with particular HLA-C alleles: in general, target 
cells expressing Cwl,  Cw3, Cw7, or Cw8 are susceptible to NK1 but resistant to NK2 clones, 
whereas target cells expressing Cw2,  Cw4,  Cw5, or Cw6 are susceptible to NK2 and resistant 
to NK1 cells. These two clusters of HLA-C alleles are distinguished by a dimorphism in the cd 
helical region, localized at amino acid positions 77 and 80.  In this report, we show that highly 
enriched  CD3+/CD56 -  cytotoxic  T  cell  sublines  and  CD3-/CD56 +  NK  sublines  derived 
from the same donor have identical cytolytic specificities when tested against a panel of alloge- 
neic LCL and various HLA-B and -C transfectant cell lines. The lysis pattern of the allogeneic 
cells appeared to be related to the NK2 specificity for both effector cells: LCL expressing HLA- 
Cw2, Cw4, Cw5, or Cw6 alleles were lysed, while LCL expressing HLA-Cwl,  Cw3, or Cw7 
molecules  were  resistant.  Resistance  to lysis could be conferred  to  susceptible  target  cells by 
transfection with a Cw*0702  gene, while expression of a Cw*0602  gene did not provide pro- 
tection. Similar patterns of HLA-C-mediated resistance were also found with two polyclonal T 
cell lines  generated  from the  peripheral  blood lymphocytes of unrelated  donors.  Thus,  major 
histocompatibility  complex  (MHC)  molecules  that  induced  resistance  to  particular  NK  cells 
also regulated  target cell resistance  to lysis by these non-MHC-restricted  effector T  cells.  For 
both types of effector cells, direct binding to HLA-C molecules was necessary to achieve inhi- 
bition  since  preincubation  with  mAb  specific  for class  I  molecules  destroyed  the  protection 
from lysis of HLA-Cw7 expressing target cells, mAbs specific for CD3 and CD8 molecules had 
no influence on lysis or inhibition of the NK-like T  cells. Formation of MHC  complexes with 
particular peptides did not appear to be essential to confer resistance, since a cell line with de- 
fective peptide  transporter  genes  (TAP  genes),  when  transfected with  an appropriate  HLA-C 
allele, was as resistant to lysis as HLA-C transfectant lines with normal TAP function.  These re- 
sults  suggest  that  HLA-C  molecules  may  deliver  negative  regulatory  signals  to  some  non- 
MHC-restricted T  cells in a manner similar to that described previously for particular NK cells. 
C 
ell surface phenotype,  cytotoxic specificity, and mode 
of activation  are three  important  parameters that dis- 
tingnish the major classes of human cytotoxic effector cells. 
For  classic  CTL,  expression  of the  coreceptor  molecules 
CD4 or CD8 governs the interaction with MHC  class II or 
class I molecules, respectively. Triggering of the TC1L-ot[3- 
CD3  complex  induces  lysis  that  is specific  for an  MHC/ 
peptide  ligand.  In  contrast,  CD16+/CD56 +  NK  cells  do 
not express TCR/CD3,  CD4, or CD8 molecules, with the 
exception that some NK cells, defined  as CD8 dim NK, dis- 
play  low  amounts  of  CD8  (1).  NK  cells  do  not  show 
MHC-restricted  target  cell  recognition,  thus  they  recog- 
nize class l-negative target cells. Unlike CTL, no single re- 
ceptor/ligand  pair  explaining  NK  target  cell  recognition 
has  been  identified.  One  positive  signal  for induction  of 
NK cytotoxicity occurs through  FclL~III (CD16)  binding 
of antibody-coated  target  cells  (2).  Interactions  of CD2 
with leukocytic function-associated-3  (CD58),  and LFA-1 
(CD 1 la) with intracellular adhesion molecule- 1 (CD54),  as 
well  as  CD27,  have  also  been  implicated  in  activation  of 
NK lytic function (3, 4, reviewed in 5). NK cells are main- 
tained  in  a  functional  state  that  enables  them  to  directly 
mediate  cytotoxic  potential,  thus  formation  of target  cell 
conjugates  via  a  number  of different  ligand  interactions 
may  be  sufficient  to  induce  target  cell  destruction.  Al- 
though  expression  of lytic  potential  in  NK  cells  does  not 
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12  (6);  furthermore,  stimulation  with  PHA  or  allogeneic 
cells can increase NK activity (7).  These modes of activa- 
tion  also induce  cytolytic activity in some  CD3 +  T  lym- 
phocytes;  these  NK-like T  cells are  not  MHC-restricted 
and they can lyse MHC  class I-negative target cells such as 
Daudi and K562  (2,  8);  for some ceils, an involvement of 
CD28 in activation is suggested (9). 
While in  many  instances the  molecules responsible for 
activation of NK cells remain undefined,  increasing infor- 
mation  is emerging about  the  role of MHC  molecules as 
inhibitory elements in NK/target cell interactions (10-12). 
Attention  to  MHC  involvement  in  NK  regulation  first 
came  through  the  observation  that  increasing MHC  ex- 
pression  on  tumor  cells  induced  NK  resistance  (13,  14), 
and transfection of some MHC  genes into  susceptible tu- 
mor cells conferred resistance to NK lysis (15).  For human 
NK  cells,  an  element  of specificity in  resistance  was  re- 
vealed with studies of defined HLA-A molecules (16).  In- 
volvement of HLA-C in providing resistance to particular 
NK cells was shown by conferring protection to susceptible 
target  cells  through  transfection  of the  HLA-Cw3  allele 
(17).  Further  work  pinpointed  a  dimorphism  in  HLA-C 
localized at  positions 77  and  80  of the  cxl-helical region 
that serves as a useful marker for HLA-C alleles capable of 
inducing resistance to selected NK cells (18-20).  More re- 
cently, resistance to other NK clones was found to be asso- 
ciated with  the  Bw4  and  Bw6  epitopes expressed by  de- 
fined HLA-B alleles (7, 21, 22). 
The  finding  that  different  HLA-A,  -B,  or  -C  alleles 
could provide resistance to particular NK populations sug- 
gests that the effector ceils express variable receptor mole- 
cules involved in mediating inhibitory signals. Several mol- 
ecules have been identified on murine and human NK cells 
that  correlate with inhibition by MHC  molecules, for ex- 
ample the murine Ly49 molecule (23),  the p58  molecular 
family (24), the NKB1  receptor (22), and the CD94 mole- 
cule  (25).  Selective  MHC  inhibition  has  only  been  de- 
scribed for NK cells, but several NK-related molecules are 
also found on some T  cells where they seem to be involved 
in regulating cytolytic activity (26, 27). 
In this study, we compared the role of HLA molecules in 
conferring  target  cell  resistance  to  lysis mediated  by  NK 
cells and non-MHC-restricted cytotoxic T  cell populations. 
These studies show that MHC  molecules that induced re- 
sistance to the NK ceils also protected target cells from lysis 
by these  particular non-MHC-restricted  T  cells.  In addi- 
tion, target cells deficient in peptide transporter genes were 
still protected  if transfected  with  an  appropriate  HLA-C 
allele. 
Materials  and Methods 
Panel  Cells  and  Tramfectants.  PBLs  of healthy Caucasian do- 
nors were HLA typed using local and International Histocompat- 
ibility Workshop sera by Dr.  R.  Wank (University of Munich, 
Munich, Germany). The HLA types of all effector and target cells 
are presented in Table 1. EBV-transformed B-lymphoblastoid cell 
lines (LCL) 1 were established from PBL in RPMI 1640  medium 
with 10% FCS, 1% PHA (PHA-m; Difco Laboratories, Detroit, 
MI), and 50% supematant medium of a 12-d culture of a marmo- 
set cell line, producing the B95.8 strain of virus (American Type 
Culture  Collection, Rockville, MD).  Daudi and  K562  are  he- 
matopoietic tumor lines that lack HLA class I expression; both are 
well known for their NK susceptibility. All LCL were maintained 
in RPMI medium with 5% FCS, 2 mM r-glutamine, 1 n~M pym- 
vate, and antibiotics. The HLA mutant cell, C1R, was described 
previously to express only HLA-Cw4 molecules (Cw*040l) and 
very  low  levels  of  HLA-B35  molecules  (B'3503)  (28).  The 
HLA-A, -B, and -C-deficient line L721.221  is hemizygous for 
chromosome 6,  and it carries a deletion of the  HLA-A and -B 
loci in the remaining MHC  (29).  The T2 line, kindly provided 
by I)r. R. Tampe (Max Planck Institute of Biochemistry, Martin- 
srmd,  Germany),  represents  a  hybrid  obtained  by  fusion  of 
L721.174  with the T-LCL CEM  (30); T2 has lost both copies of 
chromosome 6 from CEM but retains the mutant HLA haplotype 
of L721.174,  carrying the  HLA  alleles  A*0201,  B'5101,  and 
Cw*0102  (31), and it has an extensive deletion in the class 1I re- 
gion. T2 is therefore deficient in all copies of peptide transporter 
(TAP) genes and defective in peptide transport (32).  It maintains 
residual  expression  of  HLA-A2  (20-25%  of wild-type  level) 
through binding of a restricted set of signal peptides (33).  Only 
low levels of HLA-B51 are found on T2 (34); due to the lack of 
specific mAb, no conclusions can be made about HLA-Cwl sur- 
face expression. 
L721.221,  CIR,  and T2  were transfected by electroporation 
with genomic DNA of HLA genes cloned into the eucaryotic ex- 
pression vector pHEBo and selected by hygromycin B resistance 
(0.5  rag/nil)  (Boehringer Mannheim  GmbH,  Mannheim,  Ger- 
many). The HLA-B*2705 gene (35) was kindly provided by Dr. 
E.  Weiss (Institute of Human  Genetics, University of Munich, 
Munich, Germany), and the HLA-Cw*0702 gene (36) was pro- 
vided by Dr.  S. Weissman (Yale University, New Haven, CT). 
The HLA-B*3501  (37),  B'3701  (38),  and Cw'0602  (39) genes 
have been described previously by this laboratory. T2 cells trans- 
fected  with  HLA-B*3501  were  kindly  provided  by  I)r.  M. 
Takiguchi (Institute of Medical Science Tokyo, Tokyo, Japan). 
Transfectant  cell lines are designated as  .221-Cw'0702  or T2- 
Cw*0702, for example. 
Cytotoxic Effector  Lines.  Responding PBL were stimulated for 
6 d with irradiated (20  Gy) allogeneic PBL  (ratio 1:1) in 50  ml 
culture flasks in RPMI 1640 medium with 2 mM r-glutamine, 1 
mM  pyruvate,  100  U/ml  penicillin,  100  }xg/ml  streptomycin, 
and 15% heat-inactivated pooled human serum (40). The effector 
lines were  restimulated every 7-12  d  and cultured in  mediunl 
supplemented with 50-500 U/ml human rlL-2 (Proleukin; Ce- 
tus, EmeryviUe, CA) and 10% conditioned medium (41). A panel 
of sublines,  including B.3D, B.3M, B.3N,  B.3S, and B.3T,  was 
established by limiting dilution (0.3 cells per well) from a 6-d B.3 
culture in the presence of rlL-2 and irradiated feeder cells of do- 
nor 3. 
Separation  of  CD3 +  and  CD56 +  Subpopulations.  To  purify 
CD3+/CD56 -  T  cells from CD3-/CD56 § NK cells, direct and 
indirect  separations  were  performed  using  immunomagnetic 
beads  (Dynal AS,  Oslo,  Norway).  To  deplete residual CD56 + 
cells from an NK-like T  cell population (B.3S),  cells were incu- 
1Abbreviations used in this paper: LCL, lymphoblastoid cell line; RCR, rela- 
tive cytotoxic response; TAP, transporter associated  with antigen process- 
ing (genes). 
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aleah, FL) diluted 1:5 in PBS/1% FCS for 90 rain on ice. There- 
after, lgGl-coupled immunomagnetic beads  (Dynal) were added 
for 30 min at 4~  the cells binding beads were removed by mag- 
netic  adherence,  leaving  a  negative  fraction  of CD3+/CD56 - 
cells (B.3S.1).  Enrichment  of CD56+/CD3 -  NK cells was  per- 
formed by direct depletion of the contaminating CD4 + cells from 
sublines  B.3D  and  B.3T  using  CD4-coated  immunomagnetic 
beads  (Dynal) incubated for 45 min at 4~  followed by removal 
through  magnetic  adherence  resulting  in  lines  B.3D.1  and 
B.3T.1.  The  CD56 + fraction of line B.3 was positively selected 
using  the  NKH-1  mAb  and  lgGl-coupled  immunomagnetic 
beads (B.3P). All separated populations were tested for expression 
of surface markers and cytotoxic activity as described below. 
Cell-mediated  Lympholysis  Assay.  Cytotoxic  activity was  de- 
termined  in a  standard  4-h  chromium  release  assay  as described 
(42).  Spontaneous  release  was  determined  by  incubating  target 
cells  in  medium  alone.  Total  release  was  detected  by  directly 
counting an aliquot of labeled cells. The percent of lysis was cal- 
culated as follows: percent of lysis =  (experimental  cpm -  spontaneous 
cpm)/(totaI cpm -  spontaneous  cpm)  X  100. All experiments used at 
least three step titrations  of effector cells.  Standard  linear regres- 
sion analysis  was performed by plotting the percent of specific ly- 
sis against the log of the effector cell numbers.  To combine data 
from separate  experiments,  a percent relative cytotoxic response 
(RCR) was calculated as follows: percent of RCR  =  (percent of lysis 
of experimental  target~percent of lysis of reference target) ￿  100 at a se- 
lected E/T ratio, as described earlier (42). 
Cell-mediated  Lympholysis  Blocking  Using  mAbs.  To  evaluate 
the involvement of HLA class  I,  CD3,  and  CD8  molecules, re- 
spectively, in the interaction of effector cells with target cells, the 
following mAb were added to the standard chromium release as- 
say:  the pan-HLA class I-specific mAb W6/32  (ATCC) and the 
HLA-B- and -C-specific 4E ascites  (kindly provided by Dr. S. Y. 
Yang, Sloan Kettering Institute for Cancer Research, New York, 
NY) were used in dilutions ranging from 1:10 to 1:600 and were 
presented in the tables at 1:20. The MT-301  and MT-811  n~lbs 
were kindly provided as purified Ig by Dr. E. P. Rieber (Instit~t 
ffir  lmmiinologie  der  Technischen  Universit~it,  Dresden,  Ger- 
many) and were used at concentrations of 20,  10,  1, and 0.1  ~g/ 
ml. Purified mouse myeloma protein MOPC21  was included at 
the same concentrations as a negative control. Effector cells were 
preincubated  with  the (xCD3  and  c~CD8  mAbs,  and  the  target 
cells were preincubated with the HLA class I~pecific mAb for 30 
rain at room temperature.  Thereafter,  the  effector or target  cells 
were added, and chromium release was measured 4 h later. 
lmmunofluorescence Analysis.  Effector cell lines were character- 
ized for their lymphocyte composition with mAb specific for de- 
fined  surface  molecules.  Directly  labeled  FITC-  or  PE-labeled 
mAb  specific  for  CD3  (clone  UCHT1),  CD4  (clone  13B8.2), 
CD8  (clone B159)  (all  from  Immunotech,  Dianova,  Hamburg, 
Germany),  CD56  (clone NKH-1;  Coulter),  and CD16  (Leulla; 
Becton Dickinson & Co., Mountain View, CA) were used. After 
30 min incubation at 4~  and washing, staining was evaluated us- 
ing a FACScan  |  analyzer (Becton Dickinson). Surface expression 
of class I molecules was detemained using the class I~specific mAb 
W6/32 and the mouse myeloma protein UPC10 (Sigma Immu- 
nochemicals, St. Louis, MO) as a negative control. Cells were in- 
cubated with undiluted hybridoma supematants  or purified my- 
eloma  protein  (20  ~g/ml)  for 90  rain  at  4~  and  binding was 
detected with  FITC-conjugated goat anti-mouse  Ig  (F261;  Da- 
kopatts,  Copenhagen, Denmark) after 30 rain incubation at 4~ 
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Figure 1.  Cytotoxicity of the three effector populations of donor B against a panel of LCL targets. (a) Sublines B.3D and B.3M showed identical pat- 
terns of lysis with the exception of Daudi at an E/T ratio of 8:1. All LCL susceptible to lysis were members of the NK2 group  (Cw2,  Cw4, Cw5, or 
Cw6), while all resistant targets either belonged to the NK1 group  (Cwl, Cw3, or Cw7) or were NK1/NK2 heterozygous.  (b) For line B.3, two inde- 
pendent  experiments  demonstrating  that these cells have the same specificity as B.3D and B.3M are presented.  The data are given as the percentage  of 
RCR standardized to the lysis ofK562 (percent of specific lysis ranging from 59 to 65%) and using an E/T ratio of 20:1 in Exp. 1 and 30:1 in Exp. 2. 
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HLA-C-associated  Specificities  of  NK  and  Non-MHC- 
restricted  CD3 +  T  Cell  Populations.  An allogeneic MLC, 
designated as B.3, was established using responding PBL of 
donor B  and irradiated PBL of donor 3. From limiting di- 
lution cultures of B.3, two subtines (B.3D and B.3M) were 
selected that showed strong lysis of class  I  negative target 
cells (Fig.  1 a),  as did uncloned cells of line B.3  (Fig.  1 b). 
Line B.3  and  subline B.3M  lysed Daudi  and  K562  cells 
while Daudi cells were not recognized by subline B.3D in 
this experiment; however, lysis of >50% was observed us- 
ing an even lower E/T ratio of B.3D cells in other experi- 
ments not shown. In addition, all three effector populations 
showed significant lysis of some allogeneic LCL, but recog- 
nition did  not correlate with HLA molecules of donor 3 
used for allogeneic stimulation (see Table 1). 
FACS  |  analysis using mAbs directed against lymphocyte 
surface markers revealed that the two sublines were corn- 
Table 1.  HLA Antigens  of Cell Donors 
posed  of  different  lymphocyte  subtypes.  The  dominant 
fraction  of the  B.3D  subline was  CD3-/CD56 +  (93%) 
(Fig. 2  a-c) whereas the majority of B.3M cells was CD3 + 
(97%), with "~  expressing CD56  (Fig. 2  d-/~.  The phe- 
notype of line B.3  revealed a  major CD3 + fraction (97%) 
of which 18% were also CD56 + (Fig. 2 g-0- No expression 
of CD16 was  detected in these populations. The  CD3-/ 
CD56 §  phenotype of subline B.3D  prompted us to  look 
for a correlation of its specificity with MHC molecules that 
govern NK resistance, including HLA-A (16),  Bw4/Bw6 
(7, 22), and subtypes of HLA-C, as defined by variations at 
positions 77 and 80 in the al-helical region (19,  20).  No 
association was seen with HLA-A or -B, but classification 
of target cells according to  their HLA-C alleles, based on 
the  NK1  and NK2  specificities,  correlated well with  the 
pattern oflysis (Table 1).  Thus, target cells expressing two 
alleles  of the  Cw2,  Cw4,  Cw5,  and  Cw6  group  were 
strongly lysed, while target cells homozygous or heterozy- 
HLA class I serotype 
Cell  HLA-A  HLA-B  HLA-Bw  HLA-C  NK specificity* 
donor B (CP1)*  A1  B8  B57  Bw4  Bw6  Cw6  Cw7 
donor 3 (CP32)*  A32  B44  Bw6  Cw2  Cw5 
donor A (GM)*  A2  B8  B40  Bw6  Bw6  Cw7  Cw3 
donor 1 (CP41)*  A2  A3  B35  B37  Bw6  Bw4  Cw4  Cw6 
father Le (CP47)  A2  B27  B13  Bw4  Bw4  Cwl  Cw6 
mother Le (ML, CP48)  A24  A3  B35  B7  Bw6  Bw6  Cw4  Cw7 
child 1 and 2  A2  A24  B13  B35  Bw4  Bw6  Cw6  Cw4 
child3  A2  A24  B13  B7  Bw4  Bw6  Cw6  Cw7 
child 4  A2  A3  B27  B7  Bw4  Bw6  Owl  Cw7 
PR  A1  A3  B35  B70  Bw6  Bw6  Cw4  Cw4 
CP40  A2  A2  B44  B44  Bw4  Bw4  Cw5  Cw5 
WA  A1  A2  B7  B39  Bw6  Bw6  Cw7  Cw5 
CP37  A3  A30  B51  B7  Bw4  Bw6  Cwl  Cw7 
GN  A3  A31  B35  B55  Bw6  Bw6  Cw3  Cw4 
TL  A2  A24  B13  B35  Bw4  Bw6  Cw4  Cw6 
CP84  A2  A24  B27  B44  Bw4  Bw4  Cw2  Cw5 
CP89  A1  A2  B17  B44  Bw4  Bw4  Cw5 
CP14  A2  A3  B13  B18  Bw4  Bw6  Cw5  Cw6 
CP187  A3  A31  B51  B35  Bw6  Bw6  Cw6 
CPlll  AI  All  B7  B35  Bw6  Bw6  Cw3  Cw7 
CP10  A2  A3  B13  B7  Bw4  Bw6  Cw6  Cw7 
CP42  A1  A3  B35  B38  Bw6  Bw4  Cw4  Cw6 
AW  A2  A2  B15  BI8  Bw6  Bw6  Cw3  Cw7 
ClR  (B35)  --  --  --  Cw4  -- 
L721.221  ...... 
T2  A2  ....... 
NK1 
NK2 
NK1 
NK2 
NK1 
NK1 
NK2 
NK1 
NKI 
NK2 
NK2 
NK1 
NKI 
NKI 
NK2 
NK2 
NK2 
NK2 
NK2 
NK1 
NK1 
NK2 
NK1 
NK2 
NK2 
NK2 
NK2 
NK2 
NK2 
NK2 
NK2 
NK2 
* Cells are designed as NK1 or NK2, according to the classification  ofColonna et al. (20). 
Serological HLA typing was confirmed by HLA-C cDNA sequencing. 
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Figure  2.  Phenotypic  characterization  of subhnes  B.3D  and  B.3M  and  hnes  B.3  and  A.1.  The  double  staining  with  the  mAb  combinations 
CD3(FITC)/CD8(PE),  CD4(FITC)/CDS(PE), and CD3(FITC)/CD56(PE) allowed a clear distinction of the effector populations. B.3D cells expressing 
the CD56 surface molecule (95%) were not CD3, CD4, or CD8 positive, and clearly represented NK cells although the subhne contained a small fraction 
(5%) ofCD3+/CD4 + T  cells  (a-c); in contrast, B.3M expressed htde CD56 and showed high levels of CD3 and CD8, thus representing a T  cell popula- 
tion (e-J~. Lines B.3 and A.1  contained mixtures of cells with a majority ofCD3+/CD8 + or CD3+/CD4 + T  cells and very few CD3-/CD56 + NK cells 
(g-i and)-/). 
gous for Cwl, Cw3, or Cw7 alleles were poorly lysed (Fig. 
1 a). Based on this pattern, the B.3D subline would be clas- 
sified as having an NK2 specificity according to the criteria 
of Colonna  et al.  (19,  20).  The B.3D  subline  was isolated 
from  an  NK1/NK2  heterozygous  donor;  assignment  of 
HLA-Cw6  (NK2)  and  Cw7  (NK1)  by serological  typing 
was confirmed by cDNA sequencing of both HLA-C alle- 
les  (data  not  shown).  Isolation of NK2-specific  cells from 
this  donor  is in  contrast  to the  findings  of Colonna  etal., 
who  only isolated  NK2-specific  cells from NK1  homozy- 
gous donors (19, 20).  To our surprise,  the CD3+/CD8 + T 
cell subline B.3M showed a pattern oflysis identical to that 
of the NK subline (Fig.  1 a). In addition,  cells of the CD3 + 
line t3.3 cultured  for various periods of time mediated ]ysis 
of allogeneic  LCL that  correlated with  the  NK2  group  of 
HLA-C alleles: target cells lacking Cwl,  Cw3, or Cw7 ex- 
pression were more susceptible to lysis than target ceils ex- 
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pressing one of these alleles (Fig.  1 b). This pattern of spec- 
ificity  emerged  as  the  dominant  characteristic  of line  B.3 
after longer cultivation in vitro (Fig.  1 b, Exp.  1 vs Exp. 2). 
Combined,  these results suggest that the HLA-C specific~ 
ties  associated with  inhibition  of the  NK  cells  might  also 
explain  the  lysis  pattern  of these  non-MHC-restricted  T 
cells. 
HLA-C Molecules Govern Target Cell Resistance to Lysis by 
both NK and Non-MHC-restricted  T  Cells.  Two interpre- 
tations  of the lysis patterns  of these NK and  T  cells could 
be made: the effector cells may specifically recognize given 
HLA-C  alleles;  alternatively,  target  cells  with  particular 
HLA-C alleles may be resistant to lysis. The NK cells and 
the T  cells recognized at least one target cell not known to 
express HLA-C molecules  (Daudi or K562)  and allogeneic 
cells  heterozygous  for  NK1-  and  NK2-associated  alleles 
were  not  lysed;  these  results  argued  in  favor of HLA-C- Figure 3.  The cytolytic reactivity of the NK and T  cell populations 
against LCL of family Le segregates  with the HLA-C and not with HLA- 
Bw4/6  epitopes; a correlation with  HLA-Bw4/Bw6  epitopes could be 
excluded because only cells expressing the HLA-bc haplotypes were well 
lysed. They shared HLA-Bw4/Bw6 with resistant cells expressing  bd and 
ad haplotype combinations. Only the bc cells did not express an HLA-C 
molecule of the NK1 group. These results were obtained using an E/T 
ratio of 8:1 for B.3D and B.3M, and 10:1 for line B.3. 
mediated resistance to lysis. This interpretation was directly 
supported by a  segregation study in family Le  (Fig. 3);  the 
parents  are  NK1/NK2  heterozygous  (Cwl/Cw6  and 
Cw4/Cw7)  and  four  children  have  inherited  different 
combinations  of alleles  (Table  1).  All  three  effector  cell 
lines preferentially lysed cells of the two children homozy- 
gous for NK2 alleles (Cw4/Cw6),  while cells of the parents 
and  the  other  two  children were  generally resistant,  pre- 
sumably because  of Cwl  or  Cw7  expression.  HLA-Cw7 
molecules seemed to be somewhat more  effective in  con- 
ferring protection from  lysis by line B.3.  An  influence  of 
the  Bw4  and  Bw6  epitopes  in  this  family was  excluded 
since the parents are homozygous for Bw4 or Bw6, respec- 
tively. Segregation of individual HLA-B  alleles expressing 
either the Bw4  or Bw6  epitope could not explain the lysis 
pattern.  This study revealed that MHC-linked susceptibil- 
iv/to lysis by these non-MHC-restricted T  cells was reces- 
sive,  while  resistance  was  dominant,  a  characteristic  de- 
scribed previously for NK cells (11). 
Transfection of Target  Cells  with  HLA-Cw*0702  Provides" 
Protection from  Lysis  by  NK  and  Non-MHC-restricted  T 
Cells.  To  prove  a  direct involvement  of HLA-C  in  the 
inhibition oflysis, transfectant cell lines expressing different 
class I  genes  were  tested as targets for the  effector cells. A 
summary  of several  experiments  is  presented  in  Table  2. 
The MHC  deletion mutant cell line L721.221  does not ex- 
press HLA-A, -B, or -C molecules and thereby provides a 
defined system for the  analysis of single HLA genes.  Un- 
transfected L721.221  cells were lysed efficiently by all three 
effector populations.  The  L721.221  cells were  transfected 
with  three  different  HLA-B  genes:  B'2705  and  B'3701 
both encode the Bw4 epitope while Bw6 is encoded by the 
B'3501  allele. None  of these transfectant lines were resis- 
tant,  confirming that their Bw4  and Bw6  epitopes did not 
influence  these E/T  combinations.  In  contrast,  the  trans- 
fectant  line  of L721.221  expressing  HLA-Cw7  molecules 
showed strongly reduced levels oflysis as compared to  the 
parental L721.221  line and the .221-Cw*0602  cells. These 
results provided proof that expression of Cw7 directly gov- 
erned resistance to  lysis by both  the  non-MHC-restricted 
effector T  cell populations and the NK subline. 
In family Le,  resistance to lysis showed dominant segre- 
gation with  HLA haplotypes carrying NKl-related alleles. 
To  demonstrate  that  dominant  resistance  could  be  con- 
ferred  by  HLA-C  alone,  the  LCL  C1R  was  transfected 
with the HLA-Cw*0702  gene.  Because of extensive dele- 
tions in  the MHC,  C1R  only expresses HLA-Cw4  mole- 
cules at  the  cell surface in  appreciable amounts.  Since the 
Cw*040l  allele is classified in the NK2 group, transfection 
of CIR  with  HLA-Cw*0702  created  a  NK1/NK2  bet- 
Table 2.  Inhibitory Effect of the L721.221-Cw*0702  Transfectant on the Cytotoxicity of the Three Effector Lines 
Target cells 
L721.221  .221-t3"2705  .221-B'3501  .221-B'3701  .22l-Cw*0602  .221 -Cw'0702 
Effector cells  (Bw4)  (Bw6)  (Bw4)  (NK2)  (NK1) 
%  %  %  %  % 
E/T  % RCR*  % RCR  Inhibition*  % 1LCR  Inhibition  % RCR  Inhibition  % RCR  Inhibition  % RCR  Inhibition 
Line B,3  5:1  100%  83%  17%  92%  8%  104%  0%  63%  37%  31%  96% 
B,3D  3:1  100%  124%  0%  116%  0%  128%  0%  120%  0%  37%  63% 
B.3M  3:1  100%  n.t. ,~  n.t.  143%  0%  104%  0%  n.t.  n.t.  44%  56% 
*The percent of specific lysis in different experiments ranged from 43 to 81%, 
*The percent of inhibition was calculated as follows: % RCR (L721.221) -  % RCR (transfectants);  negative values are designed as 0%. 
Not tested. 
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Figure 4.  Surface  expression of the transfected HLA class I genes in 
L721.221, C1P,, and T2.  The  pan-HLA  class I-specific mAb W6/32 
clearly detected differences between the untransfected cell lines and the 
transfectants expressing Cw6 or Cw7 (a and b). Binding ofW6/32 to un- 
transfected L721.221 cells was identical to  the binding of the  negative 
control  antibody (data not shown). Untransfected Cl1< cells showed a 
low level of W6/32 binding compared to the isotype control (c, left-hand 
curves); after transfection with Cw*0702, a 500-fold increase in W6/32 
binding  was  observed  (c,  right-hand curve). B'3501,  Cw*0602,  and 
Cw*0702 transfectants  ofT2 showed a clear shift in W6/32 binding (d-f 
right-hand curves) compared to W6/32 binding of untransfected T2  cells 
(d-f, middle curves) and the isotype control (d-f left-hand curves). 
erozygous cell line, although the levels of expression of the 
two alleles were very different (Fig. 4  c). Nevertheless, the 
Cw4  expression was  sufficient to  induce  substantial resis- 
tance to lysis by an NKl-specific population that was com- 
parable to  the  resistance  of .221-Cw*0602  cells  (data not 
shown).  As shown in Fig. 5, untransfected Cl1< cells were 
strongly lysed by the NK subline B.3D  and the CD3 + line 
B.3. Expression of the HLA-Cw*0702  gene in CIR  led to 
complete  resistance.  Thus,  HLA-Cw7  expression  again 
conferred  resistance  to  lysis by both  the  NK  and  T  cells, 
which was dominant in an NK1/NK2  heterozygous cell, as 
surmised from the family study. 
Highly  Enriched  CD3 +  T  Cell Populations Are Inhibited  by 
HLA-Cw7  in a Manner Analogous  to the Purified CD56 + NK 
Lines  and the Polyclonal  T  Cell Lines.  To  demonstrate that 
enriched CD3 +  T  cells show the same pattern of cytotox- 
icity as CD56 + NK cells, four sublines were depleted of the 
contaminating  subpopulations  by  immunomagnetic  bead 
separation (Table 3). Depletion ofCD3 + cells from two in- 
dependently  generated  sublines,  B.3T  and  B.3D,  yielded 
highly  enriched  CD56 +  NK  lines  with  90%  and  98% 
CD3-/CD56  +  cells,  respectively  (Fig.  6).  The  NK  lines 
demonstrated  efficient  lysis  of  K562,  CIR,  and  .221- 
Figure 5.  HLA-Cw7 confers dominant resistance  and TAP function is 
not essential for inhibition. The NK line B.3D and the CD3 + line B.3 
showed strong lytic activity for CllL cells expressing only Cw4 and the 
HLA-deficient variant cell T2. ARer transfection with  HLA-Cw*0702, 
both target lines showed a dramatic resistance  to lysis.  T2 cells transfected 
with HLA-B*3501 or Cw*0602 remained susceptible  to lysis.  Data using 
an E/T ratio of 10:1 for both populations is presented. 
Cw*0602  cells,  but  they  were  strongly  inhibited  by  the 
HLA-Cw*0702 transfectants of C1R. and L721.221.  Linear 
regression analysis comparing the  percent  of lysis of posi- 
tively recognized target  cells with varying numbers  of ef- 
fector cells gave  significant correlation coefficients, with  r 
values that ranged from 0.9 to  1.00.  In contrast, the inhibi- 
tion  of lysis by  the  HLA-Cw7  transfectants  mostly  gave 
such  low values of lysis that  linear regression analysis was 
not meaningful. 
Subline B.3S was used to  obtain highly enriched T  cell 
populations through  CD56  depletion; after two rounds  of 
separation, CD56 + cells could no longer be detected in the 
B.3S.1  subline  (Table 3  and  Fig. 6).  Nevertheless, both T 
cell sublines showed  patterns  of lysis exactly like those  of 
the CD56 + NK lines: linear regression analysis gave signifi- 
cant  r values for the  quantitative lysis of K562,  CIlL, and 
.221-Cw*0602  cells, and  strong inhibition was  seen  with 
the  Cw*0702  transfectants  of C1R  and  L721.221.  The 
lyric activity of both T  cell sublines was less than that of the 
NK  cells;  ~10-fold  more  cells  were  needed  to  achieve 
equivalent  levels  of  cytotoxicity  (compare  B.3D.1  and 
B.3S,  Table 3).  In the absence of pure clones it is theoreti- 
cally possible that a  contaminating fraction of CD56 +  NK 
cells like those  of the  B.3D.1  subline,  yet  accounting  for 
1% of the cells in subline B.3S, was responsible for the ob- 
served  cytotoxicity.  If this  were  the  case,  however,  then 
the level of CllL lysis mediated by B.3D.1  cells at an E/T 
ratio of 0.1:1,  for  example, should  equal  that  of the  B.3S 
line at an E/T  ratio of 10:1. Estimation of the expected ly- 
sis for B.3D.1  from the regression line would give a value 
of 0, whereas 27% lysis was seen with B.3S at a  10:1  ratio. 
In fact, the lysis of CllL by B.3D.1  at  1:1  is equivalent to 
that seen with B.3S  at  10:1, yet only 1%,  not  10%,  of the 
cells  had  a  CD3-/CD56  +  phenotype.  Therefore,  it  is 
highly unlikely that the activity in  the  T  cell sublines was 
caused by residual CD3-/CD56  + NK cells. 
Separation  experiments  performed  to  isolate  CD3+/ 
1011  Falk et al. Table 3.  Cytotoxic Activity and Specificity of Separated CD3 + and CD56 + Effector Populations 
Effector cells 
Phenotype 
CD3 +  CD3 
CD56 + CD56  CD56 + CD56 
Target cells 
K562  C1R  C1R-Cw*0702  .221-Cw*0602  .221-Cw*0702 
% Lysis  % Lysis % Lysis % Inhibition  % Lysis  % Lysis % Inhibition 
2%  4%  90% 
1%  0%  98% 
1%  95%  1% 
0%  98%  0% 
13%  68%  8% 
4%  B.3T  E/T  10:1 
5:1 
2.5:1 
1%  B.3D.1  E/T  4:1 
2:1 
1:1 
3%  B.3S  E/T  10:1 
5:1 
2.5:1 
2%  B.3S.1  E/T  10:l 
5:1 
2.5:1 
11%  B.3P  E/T  10:1 
5:1 
2.5:1 
80  69  1  99  35  0  100 
75  59  2  97  25  1  96 
71  33  0  100  22  0  100 
r  1.00  0.97  0.96 
77  50  5  90  34  13  62 
76  43  7  84  32  6  81 
62  29  2  93  16  8  50 
r  0.90  0.98  0.91 
65  27  1  96  15  4  73 
57  16  0  1  O0  11  1  91 
38  12  1  92  6  2  67 
r  0.97  0.97  1.00 
48  20  2  90  19  11  42 
37  10  2  80  14  4  71 
25  7  0  10(1  3  1  67 
r  1.00  0.96  0.98 
30  0  2  9  0  100 
17  (}  {}  4  {}  10{} 
4  0  0  1  1  100 
r  1.00  0.99 
CD56 §  cells were  unsuccessful since high enrichment for 
this phenotype was not achieved (Table 3). B.3P represents 
an example of one of three lines that were  obtained after 
selection for  CD56 §  cells from line B.3  (see  Fig.  2 g-t). 
Some  reactivity directed  against K562  was  observed,  but 
lysis of C1R and .221-Cw*0602 cells was very weak or ab- 
sent.  Since  enrichment of CD3+/CD56 +  cells  required 
positive selection through the CD56-specific mAb, it may 
be that the separation procedure led to an alteration in their 
lytic  capacity.  Based  on  the  results  seen  with  the  B.3S.1 
subline, however, CD56 is not a characteristic marker for 
non-MHC-restricted T  cells showing this pattern of speci- 
ficity. 
HLA  Class 1-specific Antibodies,  but not CD3 or CD8 Anti- 
bodies,  Can Restore Lysis of Resistant Target  Cells.  Blocking 
experiments were made using various mAb to evaluate the 
involvement of HLA-class I, CD3, and CD8 molecules in 
recognition and inhibition oflysis mediated by the NK-like 
T  cells. For these experiments, target cells of two members 
of family Le used for the segregation study (Fig. 3) were se- 
lected since they expressed comparable levels of class I mol- 
ecules, yet they behaved differently as target cells.  The cell 
TL (Cw4/Cw6) was lysed while the parental ML cells ex- 
pressed  HLA-Cw7  (Cw4/Cw7)  and  were  resistant.  For 
comparison, a CD56 + NK line was included. As a control 
for  the  proper  functioning of the  mAb,  a  CD3+/CD8 + 
HLA-B35-specific CTL line was tested against both target 
cells in the presence of various concentrations ofmAb. The 
data in Table 4 are representative of three experiments and 
the values of lysis obtained in the presence of the highest 
concentration of each mAb used in each  combination are 
given. Both target cells expressed HLA-B35 (Table 1) and 
were well lysed by line GM. 1. The class I-specific reagents, 
W6/32  and  4E,  inhibited lysis  from  42  to  80%;  the  4E 
mAb was more effective. 60-80%, inhibition was observed 
with the CD3-specific mAb, whereas the CD8 mAb only 
caused 40% inhibition. In other experiments, half-maximal 
concentrations of the  CD3 and CD8 mAb were used and 
shown to cause full impairment oflysis of an HLA-A2~pe- 
cific T  cell clone (data not shown).  Thus, as  expected,  all 
mAb functioned to inhibit E/T interactions involving clas- 
sical CTL. 
Very different patterns of inhibition were seen with the 
NK-like T  cells and the NK subline compared to this clas- 
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sical  CTL.  No inhibition  of the  positive  lysis  of TL cells 
was  seen  with  any mAb;  thus,  CD3  and  CD8  molecules 
were not involved in positive recognition by the T  cells.  As 
expected, the ML cells caused strong inhibition of both ef- 
fector cells.  This inhibition was retained despite blocking of 
CD3  and  CD8  molecules  on the  NK-like  T  cells.  Once 
again,  these  molecules  were  not  found to be  involved in 
inhibition of lysis. In contrast, the inhibition of cytotoxicity 
by ML  cells  was lost when  the  target  cells  were preincu- 
bated with the class I-specific mAb. This could not be ac- 
counted  for  by  antibody-dependent,  cell-mediated  cyto- 
toxicity since neither population expressed CD16 (data not 
shown).  This dramatic  reversal of inhibition  demonstrated 
that a direct interaction with Cw7 molecules was required 
to inactivate both the NK-like T  cells  and the NK subline. 
Impaired Peptide Loading in T2 Does Not Influence the Abil- 
ity of HLA-Cw*0702  to Confer Resistance to Lysis.  The di- 
morphic variations at positions 77 and 80 that characterize 
the NK1/NK2  groups of HLA-C alleles  lie in positions of 
the  ell-helical  region,  which  could  influence  binding  of 
endogenous peptides.  Since T2 cells express no TAP1  and 
TAP2 genes,  they present  only a limited  spectrum of en- 
dogenous peptides  (33).  T2  cells were found to be highly 
sensitive to lysis by both effector cell types (Fig. 5); thus the 
Cw*0102  allele  present  in this  cell  may be  so poorly ex- 
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Figure 6.  Linear regression analysis 
and  phenotypic characterization of 
lines B.3D.1 and  B.3S.1. Lysis of 
CIR gave a linear regression with r 
values of  0.98 for the NK line B.3D.1 
(a) and 0.96 for the non-MHC-re- 
stricted T cell line B.3S.1 (c) and lysis 
of both was efficiently inhibited by 
the  Cw*0702 transfectant.  Line 
B.3D.1 represents a highly enriched 
CD3-/CD56  + population, (b) while 
line B.3S.1  is  totally depleted  of 
CD56 + cells thus only consisting of 
CD3+/CD56 - T cells (d). 
pressed  that it  cannot induce resistance.  After transfection 
with  HLA-B*3501,  HLA-Cw*0602,  or  Cw*0702,  T2 
cells showed shifts in staining with the class I-specific mAb 
W6/32,  revealing  substantial  surface  expression  of MHC 
molecules  in  all  three  transfectant  lines  (Fig.  4  d-J).  T2- 
B'3501  and T2-Cw*0602  cells remained  sensitive  to NK 
and T  cell cytotoxicity, but lysis of T2-Cw*0702 cells was 
abrogated.  Thus,  impaired  peptide  loading  in  T2  did  not 
lead to failure  of Cw7 molecules  to provide protection to 
either effector cell type. 
An  NK2  Specificity Is  Exhibited by a Second Non-MHC- 
restricted T Cell Population.  A second allogeneic effector pop- 
ulation  (line  A.1)  was  made  using  PBL  of the  NK1  ho- 
mozygous  donor  A  stimulated  with  PBL  of  donor  1. 
FACS  |  analysis demonstrated that line A.1 was 96% CD3 + 
but, like line B.3, it contained several T  cell subtypes (Fig. 
2 j-/).  Line  A.1  lysed K562  and  Daudi;  moreover,  target 
cells expressing Cw2, Cw4, Cw5, or Cw6 were susceptible 
to  lysis  while  cells  expressing  Cw7  were  clearly  resistant 
(Fig.  7  a).  Segregation analysis in family Le gave the same 
results  as  seen  with  the  effector  populations  of donor  B 
(data  not  shown).  The  HLA-Cw*0702  transfectant  of 
L721.221  was  resistant  to  lysis,  as  were  C1R-Cw*0702 
cells  (Fig.  7  b).  Impaired peptide  loading did not strongly 
influence resistance since T2-Cw*0702 cells conferred 65% Table 4.  Effects of Class I-CD3- and CD8-specific  mAb on Lysis and HLA-Cw7-mediated Inhibition 
Effector cells  E/T  mAb  Specificity 
Target cells 
TL  ML (CP48) 
Cw4/Cw6  Cw4/Cw7 
% lysis*  % lysis* 
Line GM.1  10:1  None  49  53 
B35-specific CTL  MOPC21  Control  49  52 
W6/32*  HLA-A, -B, -C  22  31 
4E  HLA-B, -  C  8  17 
MT-811r  CD3  19  10 
MT-301r  CD8  28  31 
B.3N  10:1  None  6l  3 
NK subline  MOPC21  Control  70  (l 
W6/32  r  HLA-A, -B, -C  85  63 
4E  HLA-B, -C  72  66 
MT-811r  CD3  59  3 
MT-301*  CD8  57  (I 
Line B.3  5:1  None  42  7 
NK-like T cell line  MOPC21  Control  40  8 
W6/32r  HLA-A, -B, -C  57  34 
4E  HLA-A, -  C  51  34 
MT-811'  CD3  30  3 
MT-301r  CD8  4l  3 
*Percent of lysis is given for the highest concentration of antibody tested as designated in Materials and Methods. 
CThese mAbs were shown to inhibit target cell lysis of an HLA-A2--specific  clone by 80-89% at 50% of the concentration  used here with the NK 
line B.3N and the NK-like T cell line B.3. 
inhibition  of lysis  while  T2-Cw*0602  cells  caused  only 
19%  inhibition.  Thus,  this second allogeneic combination 
produced another CD3 + line showing a  similar specificity 
to the B.3  T  cells: lysis was not related to the HLA mole- 
cules of the allogeneic stimulating cells (Table 1);  rather, it 
was dominated by HLA-Cw7-mediated resistance. 
Discussion 
Extensive  studies  of NK  clones  revealed  comFlex pat- 
terns of specificity with respect to involvement of HLA-A, 
-B,  or -C  molecules in  delivering inhibitory signals  (43), 
yet  numerous  NK  clones  seem  not  to  be  susceptible  to 
MHC  regulation (5). The various effector populations de- 
scribed in this study were highly divergent with respect to 
lymphocyte composition,  ranging  from  a  highly enriched 
(>95%)  CD3-/CD56  +  subline  (B.3D)  to  the  mixed 
CD4 §  CD8 +,  and  CD56 +  phenotypes  of the  polyclonal 
CD3 + lines B.3  and A.1  and the clear CD3+/CD8 + phe- 
notype of the T  cell subline B.3M. Additional depletion of 
CD56 +  cells  yielded  the  CD3+/CD56  subline  B.3S.1 
(99%  CD3+/CD56-),  which  showed  the same specificity 
as  the  CD3-depleted  CD56+(99%)  subline  B.3D.1.  It  is 
therefore  astonishing  that  such  homogenous  patterns  of 
cytolytic specificity were  found  in  these  populations  that 
differed 100-fold in their content of CD3 + non-MHC-re- 
stricted T  cells and CD56 + NK cells. 
The clear results obtained using single HLA gene  trans- 
fectants  demonstated  that  HLA-Cw7  molecules  not  only 
conferred resistance to the B.3D NK cells in a manner like 
that shown  for other NK cells with various HLA-C trans- 
fectants  (17,  19),  but they also protected target cells from 
lysis  by  non-MHC-restricted  CD3 +  populations.  Since 
one  target  cell with  HLA-Cwl  (father  Le)  and  one  with 
Cw3  (GN)  were not lysed, the NK1  group of HLA-C al- 
leles described by Colonna et al. (20) may detemfine resis- 
tance;  nevertheless,  studies  of larger  panels  of allogeneic 
LCL and HLA-C transfectant lines will be important to es- 
tablish the  fine  specificity of protection.  We  could block 
the inhibition of lysis by HLA-Cw7  of an  NK line and a 
non-MHC-restricted T  cell line with two HLA class I-spe- 
cific mAb. Direct binding of the effector cell to the HLA-C 
molecules expressed by the target cell is therefore necessary 
to  inhibit their lysis.  In  contrast,  lysis of targets lacking a 
protective HLA-C allele was not influenced by class I~pe- 
cific  mAbs  for  either  effector  type.  The  CD3  and  CD8 
molecules that are involved in classical CTL lysis appear to 
be irrelevant for lysis as well as for inhibition since neither 
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Daudi 
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Figure  7,  Detection of HLA-Cw7-mediated resistance to line A.1. (a) Analogous  to the results ofB.3D, B.3M, and line B.3, HLA-Cw7 was defined 
as an inhibitory molecule, (b) This resistance was confirmed in the three transfected lines expressing Cw7, .221-Cw*0702, C1R-Cw*0702, and T2- 
Cw*0702. The E/T ratio was 10:1. 
the non-MHC-restricted T  cells nor the NK cells were in- 
fluenced by blocking antibodies.  Thus,  for the NK-like T 
cells,  the  set  of molecules  interacting with  HLA-Cw7 on 
the  target  cells  is  different  from those  governing classical 
CTL recognition. 
Qualitative  changes  in  the  conformation  of the  class  I 
heavy chain-peptide-[32m  complex are  reported  to influ- 
ence  NK resistance,  and  an  increased  sensitivity  has been 
observed for some NK cells because of peptide  loading to 
MHC  molecules  (5,  44,  45)  or by addition  of [32-micro- 
globulin (46).  It is still unclear whether or not specific pep- 
tides may be required  to induce resistance, but TAP genes 
could be involved in NK resistance  (34).  Limited peptide 
specificity  in  inhibition  mediated  by  HLA-B27  to  some 
NK cells was recently demonstrated (47), leading to differ- 
ent models for peptide involvement in selective NK recog- 
nition (48).  Information with respect to HLA-C-mediated 
resistance is not yet available,  In our studies,  the compari- 
son  of  the  TAP-deficient  cell  line  T2  and  the  related 
L721.221  cell  line,  after  transfection  with  Cw*0702,  re- 
vealed no differences in resistance to NK and T  cell lysis.  It 
is not known whether the HLA-C molecules occurring on 
T2  are  devoid of peptides  or are  occupied with  a  special 
subset  of endogenous peptides,  such as signal peptides like 
those  associated  with  HLA-A2  (33).  The  binding  of the 
mAb  W6/32  to  the  T2  transfectant  cells  indicates  that 
some HLA-C molecules are associated with [32-microglob- 
ulin  since  the  epitope  recognized  by W6/32  is  only dis- 
played when  class  I  heavy chains  are  associated  with  [32- 
microglobulin  (49).  At least for HLA-A and -B molecules 
this association also requires peptide to maintain stable sur- 
face  expression  at  37~  (50).  If the  same  rules  govern 
HLA-C expression, then peptides are likely to be associated 
with these HLA-C molecules on T2; nevertheless,  substan- 
tial  alterations  in  their  composition,  as  expected from the 
TAP deficiency, did not influence protection by Cw7. Per- 
haps many peptides allow folding and display of Cw7 mol- 
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ecules in a form that confers resistance.  On the other hand, 
it is also possible that Cw7 heavy chains alone provide pro- 
tection;  if so, then such heavy chains must also be present 
on  other  transfectant  cell  lines  as  well  as  on  normal  cells 
that are resistant to lysis. 
Increasing  evidence  suggests  that  many viral  pathogens 
and tumor cells  use a variety of mechanisms to downregu- 
late  MHC  expression,  thereby  escaping  detection  by 
MHC-restricted  CTL (51).  An important  function of NK 
cells and NK-like T  cells  could be to serve as sensitive bio- 
logical  densitometers  detecting  aberrations  in  MHC  ex- 
pression.  Since  HLA-C  molecules  are  expressed  at  sub- 
stantially  lower  levels  than  HLA-A  and  -B  (52),  slight 
differences in expression  may alter the inhibitory signal in 
the  effector  cells  that  provides  protection  from  lysis  for 
normal cells.  Even minor alterations in HLA-C expression 
in  vivo  might  trigger  the  attack  of cells  harboring  such 
pathogens or carrying mutations affecting MHC expression 
by effector cells,  such as those described here. 
Others  have  shown  that  the  HLA-C specificity of NK 
clones  correlates  with  expression  of various  molecules  of 
the p58  family (53,  54).  Direct binding of a defined HLA 
class I molecule to a given p58 receptor could protect tar- 
get cells and reversion to lysis was detected in the presence 
of anti-p58  antibody (55).  Similarly the NKB1  and CD94 
(Kp43) molecules, expressed by subsets of NK cells,  are re- 
ceptor candidates involved in NK inactivation by particular 
HLA-B  molecules;  such  NK  cells  are  not  inhibited  by 
HLA-C. Some NK clones that express both CD94 and p58 
molecules have been described; they display dual specificity 
for HLA-B and -C inhibitory signals (25).  Recently, other 
antibodies  directed  against  p58  molecules  were  found  to 
bind to both NK cells and a limited subset ofCD8 + T  lym- 
phocytes  that  show  non-MHC-restricted  lytic  activity 
(26).  The  common  expression  of some  surface  receptors 
(26, 27) and overlapping cytotoxic specificities support the 
contention that some non-MHC-restricted T  cells  may be related to NK cells in their mode of activation and/or reg- 
ulation. NK and T  cells may also be derived from a  com- 
mon progenitor cell (56,  57).  Our observation that HLA- 
Cw7-mediated resistance to cytolysis is not only associated 
with a CD3-  NK cell subline but also with a CD3 + T  cell 
subline and polyclonal, non-MHC-restricted T  cell popu- 
lations provides evidence for a  regulatory relationship be- 
tween these different types ofeffector cells. It will be of in- 
terest  to  investigate  whether  the  T  cells  described  here 
express any molecules of the p58  family that are associated 
with HLA-C regulation of NK cells. 
The frequencies and specificities of the NK and NK-like 
T  cells present in an individual could reflect his pathogen 
history: intracellular pathogens that downregulate or quali- 
tatively alter MHC  expression in a locus- or allele-specific 
manner could lead to preferential selection of one group of 
effector cells, while generalized downregulation  of MHC 
molecules might select cells with several different specifici- 
ties.  This  could  contribute  to  the  wide  variations  in  the 
numbers  of cells binding  the  anti-p58,  NKB1,  or  CD94 
antibodies  found  in  different  individuals  (22,  24,  25).  If 
similar molecules  are  involved in  T  cell interactions,  this 
might  help  to  explain  why  distinct  specificities could  be 
identified in the two polyclonal T  cell lines described here. 
Alternatively, it has been shown that individual NK clones 
can express simultaneously different receptor molecules as- 
sociated  with  HLA-B-  or  -C-mediated  inhibition  (25). 
This may not be the case for T  cells, thereby limiting their 
specificities and enabling these to be defined in uncloned T 
cell lines, while this is not possible with mixed NK popula- 
tions (5). 
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